Characteristics at final study visit (n = 347) | Participants with information on PE or school attendance (n = 285) | Participants without information on PE or school attendance (n = 62) | ||
---|---|---|---|---|
N | n (%) or median (IQR) | N | n (%) or median (IQR) | |
Female, n (%) | 285 | 188 (66.0) | 62 | 39 (62.9) |
Age at disease onset, years | 285 | 5.3 (2.3–9.4) | 62 | 8.3 (3.8–11.2) |
Cumulative joint count | 285 | 6 (2–12) | 62 | 4 (2–10) |
Active joints | 285 | 0.0 (0.0–0.0) | 62 | 0.0 (0.0–0.0) |
Physician GA, VAS | 192 | 0.0 (0.0–0.9) | 4 | 0.3 (0.1–1.8) |
Patient/parent GA, VAS | 216 | 0.0 (0.0–1.2) | 3 | 0.3 (0.0–0.5) |
Pain VAS | 220 | 0.0 (0.0–1.3) | 3 | 0.0 (0.0–0.5) |
CHAQ score | 285 | 0.0 (0.0–0.1) | 8 | 0.0 (0.0–0.1) |
CHQ-PF50, PhS score | 160 | 52.5 (45.5–56.9) | 4 | 46.8 (36.2–53.9) |
CHQ-PF50, PsS score | 160 | 54.8 (48.0–59.6) | 4 | 40.9 (32.4–46.8) |
DMARDs, n (%) | 285 | 102 (35.8) | 62 | 8 (12.9) |
Oligoarticular persistent, n (%) | 285 | 84 (29.5) | 62 | 25 (40.3) |
Oligoarticular extended, n (%) | 285 | 49 (17.2) | 62 | 8 (12.9) |
Polyarticular RF negative, n (%) | 285 | 58 (20.3) | 62 | 7 (11.3) |
Polyarticular RF positive, n (%) | 285 | 2 (0.7) | 62 | 1 (1.6) |
Systemic arthritis, n (%) | 285 | 8 (2.8) | 62 | 1 (1.6) |
Psoriatic arthritis, n (%) | 285 | 13 (4.6) | 62 | 0 (0) |
Enthesitis-related arthritis, n (%) | 285 | 29 (10.2) | 62 | 12 (19.3) |
Undifferentiated arthritis, n (%) | 285 | 42 (14.7) | 62 | 8 (12.9) |
ESR mm/hour | 193 | 7.0 (4.0–11.0) | 14 | 8.5 (6.0–14.0) |
CRP mg/liter | 201 | 0.0 (0.0–5.0) | 12 | 2.5 (0.0–7.5) |
RF positive, n (%) | 150 | 5 (3.3) | 29 | 2 (6.9) |
HLA-B27 positive, n (%) | 274 | 62 (22.6) | 52 | 11 (21.2) |
ANA positive, n (%) | 284 | 66 (23.2) | 60 | 13 (21.7) |